Beacon Biosignals Collaborates With Harmony Biosciences To Incorporate Quantitative EEG Measurements Into Two Of Harmony's Phase 3 Studies Of HBS-301 For Narcolepsy And Idiopathic Hypersomnia

Benzinga · 1d ago

Beacon Biosignals, a leader in AI-driven neurophysiology and precision drug development, today announced a collaboration with Harmony Biosciences (NASDAQ:HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for rare neurological disorders, to incorporate quantitative electroencephalography (EEG) measurements into two of Harmony's Phase 3 studies of HBS-301 for Narcolepsy and Idiopathic Hypersomnia.

The collaboration will support Harmony's primary objective of assessing excessive daytime sleepiness (EDS) by complementing traditional patient-reported outcomes, such as the Epworth Sleepiness Scale (ESS), with objective sleep EEG data.